Company News

Lonza Expands Peptide API Manufacturing at Visp Facility

2024-10-22
Lonza Expands Peptide API Manufacturing at Visp Facility

Lonza expands peptide API manufacturing capacity at its Visp site, adding commercial-scale SPPS infrastructure for long-term peptide supply contracts.

Lonza Group has announced the expansion of its peptide manufacturing facility in Visp, Switzerland. The move is a strategic initiative that enhances Lonza's role as a dominant player in the global peptide API segment, capable of meeting the increasing need for personalized medicine and biologics. The expansion adds commercial-scale SPPS infrastructure and integrated services to serve long-term peptide supply contracts. This investment positions Lonza to capture growing demand from pharmaceutical companies developing GLP-1 receptor agonists and other peptide-based therapeutics.
Read Full Source Article

Hope to become your Partner

Contact us on Telegram for product inquiries, pricing, and orders.

Contact on Telegram
MINSTAR

Shanghai Minstar Chemical Co., Ltd.
RAW API Supplier | Q2 2026 Catalogue.
Shipping from USA and International warehouses.

All products for research use only, not for human or veterinary use, no sales to individuals.

Quick Links

Official Contact

Building 8, No. 1098, Chuansha Road,
Pudong, Shanghai, China

© 2026 Shanghai Minstar Chemical Co., Ltd. All Rights Reserved. | Prices subject to change without notice.